Autoantigen Combination Therapy via Intralymphatic Tolerance Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monotherapies and combination regimens for autoimmune diseases such as type 1 diabetes have failed to show clinically meaningful effects, and there is a need for a treatment that can establish long-term tolerance to multiple self-antigens without chronic non-specific systemic immune suppression.
Innovation Solution
A combination regimen involving β cell autoantigens, anti-inflammatory compounds, and vitamin D is administered to induce tolerogenic dendritic cells, promoting regulatory T cells and antigen presenting cells to establish tolerance to multiple self-antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapies or combination regimens are used to treat autoimmune diseases, then immune responses are modulated, but clinically meaningful effects are not achieved and long-term tolerance is not established
Solution Approach 1:
The patent combines multiple self-antigens (insulin, GAD65, IA-2) into a single vaccine formulation administered via intralymphatic injection. This merging of multiple antigen targets into one delivery system aims to establish comprehensive tolerance to multiple β-cell antigens simultaneously, addressing the inadequacy of single-antigen or separate-administration approaches that have failed to produce clinically meaningful effects
Solution Approach 2:
The patent uses vitamin D as an intermediary substance that modulates the immune response to the antigen combination. Vitamin D enhances the tolerogenic effect of the self-antigen vaccine by promoting regulatory T cell development and function, thereby mediating the establishment of long-term tolerance that neither the antigens alone nor conventional immunosuppressants can achieve
2Object-affected harmful factors
If conventional immunosuppression is used to reduce autoimmune responses, then immune activity is suppressed, but non-specific systemic suppression occurs with significant side effects
Solution Approach 1:
The patent employs intralymphatic injection to deliver the antigen combination directly to lymph nodes, creating a localized immunomodulatory effect at the site of immune cell activation. This local delivery method selectively targets autoimmune responses in the lymphatic system while minimizing systemic immunosuppression, thereby reducing side effects associated with conventional broad-spectrum immunosuppressants
Solution Approach 2:
The patent changes the delivery route parameter from conventional subcutaneous or intramuscular injection to intralymphatic injection. This parameter change directs the vaccine to the lymph nodes where antigen-presenting cells and T cells are concentrated, enhancing the tolerogenic effect while reducing the dose required and minimizing systemic exposure and side effects
3Duration of action of stationary object
If continuous dosing is administered to maintain treatment effect, then tolerance is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The patent administers a combination of multiple self-antigens (insulin, GAD65, IA-2) in a single intralymphatic injection as a preliminary action that establishes broad tolerance to multiple β-cell antigens simultaneously. This comprehensive initial dosing aims to create long-lasting tolerance that reduces or eliminates the need for continuous follow-up dosing, thereby simplifying the treatment regimen while maintaining durable treatment effect
Solution Approach 2:
The vaccine formulation contains multiple self-antigens that target different autoimmune pathways and T cell specificities involved in β-cell destruction. This multi-functional antigen combination addresses multiple aspects of the autoimmune response in a single intervention, potentially establishing comprehensive and lasting tolerance that reduces treatment frequency and complexity
Data Source
AI summary
Provided herein, among other things, is a method for prevention and/or treatment of an autoimmune disease. In some embodiments, the method may comprise administering to a subject a composition, said composition comprising at least one β cell autoantigen, by intralymphatic injection or injection directly into a lymph node.